LAWRENCE, Mass., March 31, 2015 /PRNewswire/ -- NxStage® Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. 

                            
                            
                                  
      
      
      
      
      
      
      
                                  
                                    NXTM, -0.46%

                            
                                  
      
      
      
      
      
      
      
                                         today announced the opening of its Greenbelt, Maryland dialysis center, offering patients several flexible therapy options. Conveniently located just off the DC Beltway between Baltimore and Washington DC, the center boasts a team of highly trained medical staff committed to providing high quality, personalized and compassionate care to dialysis patients and their families.


                  The facility offers multiple therapy options using the NxStage System One™ including home hemodialysis, home nocturnal hemodialysis, flexible in-center hemodialysis, and short-term respite care. Additionally, the center offers peritoneal dialysis therapy. All NxStage Kidney Care centers feature home dialysis training customized to meet the needs of each patient.


                  "At NxStage Kidney Care, we provide high-quality, individualized, flexible dialysis care," said Dr. Ashte Collins, Medical Director at NxStage Kidney Care Greenbelt. Dr. Collins is an Assistant Professor of Medicine at The George Washington University (GWU) School of Medicine & Health Sciences. "We listen to each patient's needs, and with the help of a clinician and care team, develop an optimal course of therapy that combines safety, efficacy, and flexibility."


                  Dr. Collins leads a skilled team of nurses and clinicians, including a dedicated renal social worker who provides patients with education and support throughout the kidney transplant process. The center also staffs a registered dietitian who works with patients to create customized nutritional and lifestyle plans. Like all NxStage Kidney Care facilities, the Greenbelt, MD center is furnished with modern, comfortable amenities, offering a relaxed therapy environment.


                  "Our expansion into Prince George County will provide access to flexible dialysis options for both patients and physicians in the region," said Robert Brown, President of NxStage Kidney Care. "We are very excited to offer our quality dialysis services right next to our nation's capital, and we invite all patients in the area to tour our new center, meet our remarkable staff, and experience NxStage Kidney Care for themselves."


                  NxStage Kidney Care Greenbelt is located at 10003 Derekwood Lane, Suite 100 & 145, Lanham, MD 20706. For more information about NxStage Kidney Care's home and flexible in-center dialysis options in Greenbelt please visit www.nxstagekidneycare.com.


                  
        About NxStage Kidney Care 
        NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. 

                            
                            
                                  
      
      
      
      
      
      
      
                                  
                                    NXTM, -0.46%

                            
                                  
      
      
      
      
      
      
      
                                         is innovating a dialysis care model that is intended to support and encourage patient centered care and provide enhanced access to the life-changing benefits of home therapy as well as flexible in-center options. By leveraging NxStage's home leadership and the innovative technology of its System One, NxStage Kidney Care is committed to helping patients take control of their dialysis and to allowing physicians the flexibility to prescribe what is truly best for their patients. For more information, please visit www.nxstagekidneycare.com or call (866) 694-2707.


                  
        About NxStage MedicalNxStage Medical, Inc. 

                            
                            
                                  
      
      
      
      
      
      
      
                                  
                                    NXTM, -0.46%

                            
                                  
      
      
      
      
      
      
      
                                         is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.


                  
        Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


                  
        Media contact:   

Kristen K. Sheppard, Esq.  

 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
   

Tel: (978) 332-5923


                  Logo - http://photos.prnewswire.com/prnh/20141008/150974

                  To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-kidney-care-brings-innovative-dialysis-options-to-prince-george-county-300057807.html

                  SOURCE  NxStage Kidney Care, Inc.


                  
        
      

                  Copyright (C) 2015 PR Newswire. All rights reserved


    

                            
                            
                                  
      
      
      
      
      
      
      
      


                
            

...

Zeng Si Wang^*, Fei Xiong, Xiao Hang Xie, Dan Chen, Jian Hua Pan and Li Cheng

• * Corresponding author: Zeng S Wang This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Author Affiliations

Department of Nephrology, Wuhan No.1 Hospital, Wuhan 430000, Hubei Province, PR China

For all author emails, please log on.

BMC Nephrology 2015, 16:44  doi:10.1186/s12882-015-0031-7

Abstract (provisional)

Background Diabetic nephropathy (DN) is a major cause of Chronic Kidney Disease and End-Stage Renal Disease throughout the world; however, the reversibility of diabetic nephropathy remains controversial. Endoplasmic reticulum (ER) stress plays an important role in the pathogenesis of DN. Astragaloside IV (AS-IV) is derived from Astragalus membranaceus (Fisch) Bge, a widely used traditional herbal medicine in China, and has diverse pharmacological activities including the attenuation of podocyte injury and amelioration of proteinuria in idiopathic nephrotic syndrome. The present study aimed to investigate the effect and mechanism of AS-IV on proteinuria in the rat streptozotocin (STZ)-induced model of diabetes. Methods Male Sprague–Dawley (SD) rats were randomly divided into four groups: normal control (Normal group), diabetic nephropathy (Model group), diabetic nephropathy plus AS-IV treatment (AS-IV group) and diabetic nephropathy plus 4-phenyl butyric acid treatment (PBA group). ER stress was induced in cultured human podocytes, pretreated with or without AS-IV, with tunicamycin (TM). At the end of 8 weeks, serum creatinine (Scr), blood urea nitrogen (BUN) and 24-hour urinary protein excretion rate (UAER) were determined. Renal morphology was examined after periodic acid-Schiff staining of kidney sections. Apoptosis of podocytes was measured by flow cytometry. The total expression and phosphorylation of eIF2?, PERK and JNK, and the expression of CHOP and cleaved caspase-3 were determined by western blotting. The expression of glucose-regulated protein 78 (GRP78) and 150 kDa oxygen-regulated protein (ORP150) mRNA and protein was determined by real-time PCR and western blotting respectively. Results AS-IV treatment significantly reduced urinary albumin excretion, plasma creatinine and blood urea nitrogen levels, and prevented the mesangial matrix expansion and increase in mean mesangial induced by STZ. AS-IV also prevented the phosphorylation of eIF2?, PERK and JNK, and inhibited the expression of GRP78 and ORP150 markedly, both in vivo and in vitro. AS-IV inhibited the TM-induced apoptosis of podocytes, concomitant with decreased CHOP expression and cleaved caspase-3. Conclusions This study supports the hypothesis that AS-IV reduces proteinuria and attenuates diabetes, which is associated with decreased ER stress. This might be an important mechanism in the renoprotective function of AS-IV in the pathogenesis of DN.

...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jmjl38/renal) has announced the addition of the "Renal Stones/Calculi Global Clinical Trials Review, H1, 2015" report to their offering.

Renal Stones/Calculi Global Clinical Trials Review, H1, 2015" provides data on the Renal Stones/Calculi clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Renal Stones/Calculi. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Renal Stones/Calculi.

Reasons to buy

• Understand the dynamics of a particular indication in a condensed manner
• Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
• Obtain discontinued trial listing for trials across the globe
• Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Top Companies Participating in Renal Stones/Calculi Therapeutics Clinical Trials

• Astellas Pharma Inc.
• The Himalaya Drug Company
• Omeros Corporation
• Allena Pharmaceuticals, Inc.
• Indus Biotech Private Limited
• Hamad Medical Corporation
• Catalysis, S.L.
• Actavis plc

For more information visit http://www.researchandmarkets.com/research/jmjl38/renal

...

Acute kidney injury Proximal tubule cells modulate inflammation after renal injury Nature.com They found that the renal tubules of mice that expressed a functionally deficient form of KIM-1 (KIM-1?mucin) contained greater numbers of apoptotic bodies and cellular debris after ischaemia/reperfusion (I/R) than did those of wild-type mice. Further ...

...